Citadel Advisors’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.04M | Sell |
337,900
-85,300
| -20% | -$362K | ﹤0.01% | 7570 |
|
|
2025
Q4 | $1.53M | Buy |
423,200
+53,500
| +14% | +$233K | ﹤0.01% | 6463 |
|
|
2025
Q3 | $1.39M | Buy |
369,700
+109,000
| +42% | +$421K | ﹤0.01% | 6816 |
|
|
2025
Q2 | $1.01M | Sell |
260,700
-55,600
| -18% | -$301K | ﹤0.01% | 7063 |
|
|
2025
Q1 | $1.58M | Buy |
316,300
+72,000
| +29% | +$456K | ﹤0.01% | 5988 |
|
|
2024
Q4 | $1.76M | Sell |
244,300
-61,400
| -20% | -$469K | ﹤0.01% | 5890 |
|
|
2024
Q3 | $1.88M | Buy |
305,700
+39,400
| +15% | +$267K | ﹤0.01% | 5657 |
|
|
2024
Q2 | $1.77M | Sell |
266,300
-49,400
| -16% | -$365K | ﹤0.01% | 5544 |
|
|
2024
Q1 | $3.21M | Buy |
315,700
+71,100
| +29% | +$723K | ﹤0.01% | 4658 |
|
|
2023
Q4 | $2.75M | Buy |
244,600
+129,300
| +112% | +$540K | ﹤0.01% | 4803 |
|
|
2023
Q3 | $300K | Buy |
115,300
+11,800
| +11% | +$33.9K | ﹤0.01% | 9172 |
|
|
2023
Q2 | $365K | Sell |
103,500
-170,700
| -62% | -$766K | ﹤0.01% | 8614 |
|
|
2023
Q1 | $1.16M | Buy |
274,200
+93,800
| +52% | +$1.11M | ﹤0.01% | 6459 |
|
|
2022
Q4 | $2.97M | Sell |
180,400
-101,200
| -36% | -$1.14M | ﹤0.01% | 4766 |
|
|
2022
Q3 | $3.6M | Buy |
281,600
+104,000
| +59% | +$1.54M | ﹤0.01% | 4450 |
|
|
2022
Q2 | $2.08M | Buy |
177,600
+57,500
| +48% | +$355K | ﹤0.01% | 5469 |
|
|
2022
Q1 | $731K | Buy |
120,100
+700
| +0.6% | +$5.16K | ﹤0.01% | 8461 |
|
|
2021
Q4 | $1.09M | Sell |
119,400
-62,600
| -34% | -$665K | ﹤0.01% | 7722 |
|
|
2021
Q3 | $2.06M | Buy |
182,000
+121,200
| +199% | +$1.47M | ﹤0.01% | 6275 |
|
|
2021
Q2 | $599K | Sell |
60,800
-47,100
| -44% | -$644K | ﹤0.01% | 9624 |
|
|
2021
Q1 | $1.52M | Buy |
107,900
+12,200
| +13% | +$197K | ﹤0.01% | 7053 |
|
|
2020
Q4 | $1.08M | Buy |
95,700
+28,700
| +43% | +$338K | ﹤0.01% | 6651 |
|
|
2020
Q3 | $884K | Sell |
67,000
-219,900
| -77% | -$4.4M | ﹤0.01% | 6254 |
|
|
2020
Q2 | $3.07M | Buy |
286,900
+230,900
| +412% | +$1.27M | ﹤0.01% | 3822 |
|
|
2020
Q1 | $180K | Buy |
56,000
+34,800
| +164% | +$80K | ﹤0.01% | 8114 |
|
|
2019
Q4 | $40K | Buy |
21,200
+1,400
| +7% | +$2.59K | ﹤0.01% | 8806 |
|
|
2019
Q3 | $39K | Buy |
19,800
+3,300
| +20% | +$7.32K | ﹤0.01% | 8776 |
|
|
2019
Q2 | $39K | Sell |
16,500
-49,700
| -75% | -$133K | ﹤0.01% | 8805 |
|
|
2019
Q1 | $192K | Buy |
66,200
+52,300
| +376% | +$156K | ﹤0.01% | 8236 |
|
|
2018
Q4 | $29K | Buy |
+13,900
| New | +$49.2K | ﹤0.01% | 8627 |
|
|
2017
Q1 | – | Sell |
-148
| Closed | -$144K | – | 7387 |
|
|
2016
Q4 | $144K | Buy |
+148
| New | +$133K | ﹤0.01% | 6528 |
|
|
2014
Q3 | – | Sell |
-12
| Closed | -$5K | – | 8076 |
|
|
2014
Q2 | $5K | Buy |
12
+4
| +50% | +$1.81K | ﹤0.01% | 7716 |
|
|
2014
Q1 | $4K | Buy |
+8
| New | +$4.67K | ﹤0.01% | 7674 |
|
|
2013
Q3 | – | Sell |
-59
| Closed | -$28K | – | 6696 |
|
|
2013
Q2 | $28K | Buy |
+59
| New | +$29.3K | ﹤0.01% | 5925 |
|
Other funds holding ALT
VCM
VPM
N
Citadel Advisors's ALT Position: Q1 2026 in Review
Citadel Advisors reduced its Altimmune (ALT) stake by 66% in Q1 2026, selling an estimated $3.77M and leaving 448,873 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #6905.
Citadel Advisors first reported a position in ALT in Q1 2014 and has held it in 35 quarters since. The position peaked at $19.1M in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Citadel Advisors held 448,873 shares of Altimmune worth $1.38M as of Q1 2026.
- Citadel Advisors sold 889,054 Altimmune shares in Q1 2026, an estimated $3.77M.
- Altimmune made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6905 holding.
- Citadel Advisors first reported a position in Altimmune in Q1 2014 and has held it in 35 quarters since.
- Citadel Advisors's Altimmune position peaked at $19.1M in Q4 2022.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.